Nitin Karandikar, MD, PhD’s research laboratory focuses on the immune processes that underlie the pathogenesis of multiple sclerosis, which is an immune-mediated demyelinating disease of the central nervous system (CNS). His research group was the first to show the unexpected finding that CD8+ T cells targeted toward CNS antigens can suppress disease activity and could potentially be used as a therapeutic approach.